Leucosceptrane Sesterterpenoids as a New Type of Natural Immunosuppressive Agents in Treating Sepsis

J Med Chem. 2024 Jan 11;67(1):513-528. doi: 10.1021/acs.jmedchem.3c01759. Epub 2023 Dec 27.

Abstract

Intragastric administration of the total sesterterpenoid extract (TSE) of medicinal plant Leucosceptrum canum at 2.5 g/kg dose protected mice from LPS-induced sepsis. Phytochemical investigation led to the isolation and identification of 47 leucosceptrane sesterterpenoids (1-47) including 30 new compounds (1-30) with complicated oxygenation patterns. Biological screening indicated their immunosuppressive activity via inhibiting IFN-γ secretion and/or proliferation of T cells with different potencies. Mechanism study of compounds 9, 25, and 32 revealed that they inhibited the activations of AKT-mTOR, JNK, p38 MAPK or ERK pathway in T cells and macrophages. In addition, compounds 9 and 25 induced G0/G1 cell arrest of T cells. The major component, leucosceptroid N (32), significantly lowered the levels of IL-6 and TNF-α in peripheral blood serum, and ameliorated the multiorgan damages of LPS-induced sepsis mice at 25 mg/kg dose. These findings suggest that leucosceptrane sesterterpenoids are a new type of potential immunosuppressive agents for sepsis treatment.

MeSH terms

  • Animals
  • Immunosuppressive Agents* / metabolism
  • Immunosuppressive Agents* / pharmacology
  • Immunosuppressive Agents* / therapeutic use
  • Lipopolysaccharides / metabolism
  • Macrophages / metabolism
  • Mice
  • Sepsis* / chemically induced
  • Sepsis* / drug therapy
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Immunosuppressive Agents
  • Lipopolysaccharides
  • Tumor Necrosis Factor-alpha